TriangleHEALTH PROFESSIONAL · SOURCE READING
NLPHL
Source: Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 16, 2025 · Captured 2026-09-09.
Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.
Table 10 summarizes the results of treatment approaches used for pediatric patients with NLPHL, some of which feature surgery alone for completely resected disease and limited cycles of chemotherapy with or without LD-IFRT. Because of the relative rarity of this subtype, most trials are limited by small cohort numbers and nonrandom allocation of treatment.
Source links and citations
| Chemotherapy (No. of Cycles)a | Radiation (Gy) | No. of Patients | Event-Free Survival Rate (No. of Years of Follow-up) | Survival Rate (No. of Years of Follow-up) |
|---|---|---|---|---|
| IFRT = involved-field radiation therapy; N/A = not applicable; No. = number. | ||||
| aFor more information about the chemotherapy regimens, see Table 6. | ||||
| bSingle lymph node surgically resected. | ||||
| cAll involved lymph nodes surgically resected. | ||||
| CVP (3) [65] | None | 55 | 74% (5) | 100% (5) |
| Noneb [27] | Noneb | 52 | 77% (5) | 100% (5) |
| AV-PC [27] | None | 124 | 85.5% (5) | 100% (5) |
| IFRT (21) | 11 | |||
| Nonec [28] | None | 51 | 67% (2) | 100% (2) |
Publication references
Read the original reference and check its publication notices.
Preserved source evidence · Not medical advice